The first week of August brought no single blockbuster verdict to reset trial values, but it delivered something practitioners should track more closely than any one number: movement on the structural fights that decide how plaintiff cases get funded, disclosed, and resolved. Here is what moved and why it matters for case-building.
A federal funding-disclosure bill lands in the Senate
The push to force disclosure of third-party litigation funding reached the federal level with the introduction of the Litigation Funding Transparency Act of 2026. Sponsored by Senators Chuck Grassley, Thom Tillis, John Kennedy, and John Cornyn, the bill would require parties in federal class actions and multidistrict litigation to disclose the existence of outside funding and to produce the underlying agreements. By its terms it reaches large coordinated proceedings, those involving one hundred or more cases, which is to say the MDLs where funding is most common.
A Senate introduction is not a statute, and this one faces the same headwinds that have stalled prior versions. The significance is the direction of travel. Georgia's funding-disclosure law took effect at the start of the year, Texas business interests are pressing for both funding transparency and medical-damages limits, and the federal bill signals that the disclosure fight is no longer confined to statehouses. Plaintiff firms that rely on portfolio financing should assume the disclosure question will follow their MDL inventory, and should paper their funding relationships with that assumption in mind.
The practical exposure is not only strategic. A funding agreement produced in discovery invites argument about control, about who is really driving settlement decisions, and about whether the plaintiff can afford to hold out. Firms that keep their financing terms clean, non-recourse, and free of any control provision have far less to fear from a disclosure regime than firms whose agreements read like the funder is running the case.
Camp Lejeune crosses a milestone, but the pace fight continues
The Camp Lejeune docket reached a reporting milestone, with settlement offers now exceeding $968 million and payouts topping $801 million. That sounds like momentum until it is measured against the denominator. More than 400,000 administrative claims remain pending, the elective option fast track covers only about 12 percent of them, and the Congressional Budget Office has pegged the government's total exposure as high as $21 billion. The court has set an October 30 target for a global framework.
The live dispute is the offset. The Justice Department is pressing the position that the statute requires courts to subtract VA, Medicare, and Medicaid benefits tied to the exposure from any award, a reading that would meaningfully shrink net recoveries for the sickest claimants, who tend to carry the largest collateral benefits. How that question resolves will ripple beyond Lejeune, because it previews the collateral-source and reimbursement math that governs every federal-benefit client. Our liens and settlement coverage has tracked how those offsets get litigated on the individual file.
Depo-Provera turns toward settlement
The Depo-Provera brain-tumor litigation took a decisive turn. Pfizer reached an agreement in principle to resolve a group of cases, the first significant settlement development in the MDL, and the presiding judge vacated the remaining pretrial and bellwether deadlines while the parties work out terms. The docket had continued to grow into the settlement posture, adding several hundred cases over the summer to reach roughly 5,830.
Vacating bellwether dates before a single trial is a notable posture. It suggests the parties see enough shared exposure to justify a framework without the price discovery a bellwether provides. For firms holding Depo-Provera inventory, the practical questions now are participation thresholds, the point system that will value individual claims, and the lien exposure on the medical treatment that supports each case. Those are settlement-accounting questions, not liability questions, and they will decide what each client actually nets.
Talc and NEC keep the MDL calendar full
The talc litigation remains the largest mass-tort docket in the country at more than 68,000 active cases. Johnson & Johnson's proposed $5.5 billion resolution of roughly 70,000 ovarian-cancer claims is still contingent on the participation threshold that has sunk the company's prior attempts, reported at 95 percent of eligible plaintiffs. The company has lost repeatedly when these cases reach a jury, which is the leverage keeping claimants at the table and the reason the participation math is the whole ballgame.
The NEC baby-formula litigation, meanwhile, keeps its trial calendar active, with more than 750 cases in the federal MDL and bellwether trials set across August and November of this year and into February. The bellwether results will supply the first real valuation signal for a docket that has grown steadily without one. Firms weighing whether to keep taking NEC intake should watch those verdicts before committing more capital, a discipline our practice operations coverage keeps returning to.
Verdict watch
The verdict that should catch the auto and products bar came out of Broward County, where a jury returned roughly $603 million to the estate and family of a 22-year-old woman killed when a counterfeit airbag allegedly ruptured during a minor collision. The theory is worth noting apart from the number. A low-speed crash that should have been survivable became fatal because of a counterfeit component in the vehicle's safety system. Counterfeit and gray-market parts are a growing evidentiary theme, and the case is a reminder to preserve the failed component and trace its chain of custody before it disappears into a salvage yard. Our product liability coverage has detailed how those preservation fights play out.
A Prince George's County jury separately awarded more than $71 million to a man who suffered catastrophic injuries after jumping from a second-story window during a nighttime apartment fire, a premises and habitability theory that continues to produce near-nine-figure results in the right venue. The common thread with the airbag case is causation built on physical evidence rather than sympathy, and both verdicts reward the plaintiff teams that invested in reconstruction early.
The state-reform backdrop keeps tightening
None of the federal developments are happening in a vacuum. The defense bar and business coalitions have spent 2026 pressing the same package at the state level: funding disclosure, phantom-damages limits that tie past-medical recovery to amounts actually paid rather than amounts billed, and caps on non-economic damages. Georgia's reforms are now in force, Texas interests are lobbying for a medical-damages fix, and several other states have similar measures in various stages. The cumulative effect is a squeeze on two fronts at once, on how cases are financed and on how the largest damages category, the medical specials, gets proven and valued.
For plaintiff firms the practical response is to build the billed-versus-paid record early and to document the reasonable value of care through treating providers and, where needed, a billing expert. A reform that limits recovery to negotiated or paid amounts rewards the firm that has the reasonable-value evidence ready and punishes the one that assumed the chargemaster number would hold. This is the settlement-accounting discipline that used to be an afterthought and is now central to the net result.
What to take into next week
The pattern across all of it is that the money is increasingly decided by structure rather than liability. Whether funding must be disclosed, how collateral benefits offset a federal recovery, what participation threshold a global deal requires, and how a point system values an individual MDL claim are the questions setting net outcomes. Liability still has to be proven, but the practitioners capturing value in 2026 are the ones treating the settlement and disclosure architecture as a core competency rather than back-office cleanup.
We will track each of these as they develop, from the funding bill's committee posture to the Lejeune offset ruling to the first NEC bellwether. For the individual-file version of these same fights, our auto, products, and lien coverage runs alongside this weekly recap.